Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma
Author: Field, K.
Simes, J.
Nowak, A.
Cher, L.
Wheeler, H.
Hovey, E.
Brown, C.
Barnes, E.
Sawkins, K.
Livingstone, A.
Freilich, R.
Phal, P.
Fitt, G.
Rosenthal, M.
Arzhintar, I.
Garrett, L.
Byrne, A.
Dowling, A.
Ranieri, N.
Jennens, R.
et al.
Citation: Neuro-Oncology, 2015; 17(11):1504-1513
Publisher: Oxford University Press
Issue Date: 2015
ISSN: 1522-8517
Statement of
Kathryn M. Field, John Simes, Anna K. Nowak, Lawrence Cher ... W.K. Patterson ... N. Singhal ... et al.
Abstract: Background: The optimal use of bevacizumab in recurrent glioblastoma (GBM), including the choice of monotherapy or combination therapy, remains uncertain. The purpose of this study was to compare combination therapy with bevacizumab monotherapy. Methods: This was a 2-part randomized phase 2 study. Eligibility criteria included recurrent GBM after radiotherapy and temozolomide, no other chemotherapy for GBM, and Eastern Cooperative Oncology Group performance status 0–2. The primary objective (Part 1) was to determine the effect of bevacizumab plus carboplatin versus bevacizumab monotherapy on progression-free survival (PFS) using modified Response Assessment in Neuro-Oncology criteria. Bevacizumab was given every 2 weeks, 10 mg/kg; and carboplatin every 4 weeks, (AUC 5). On progression, patients able to continue were randomized to continue or cease bevacizumab (Part 2). Secondary endpoints included objective radiological response rate (ORR), quality of life, toxicity, and overall survival (OS). Results: One hundred twenty-two patients (median age, 55y) were enrolled to Part 1 from 18 Australian sites. Median follow-up was 32 months, and median on-treatment time was 3.3 months. Median PFS was 3.5 months for each arm (hazard ratio [HR]: 0.92, 95% CI: 0.64–1.33, P = .66). ORR was 14% (combination) versus 6% (monotherapy) (P = .18). Median OS was 6.9 (combination) versus 7.5 months (monotherapy) (HR: 1.18, 95% CI: 0.82–1.69, P = .38). The incidence of bevacizumab-related adverse events was similar to prior literature, with no new toxicity signals. Toxicities were higher in the combination arm. Part 2 data (n = 48) will be reported separately. Conclusions: Adding carboplatin resulted in more toxicity without additional clinical benefit. Clinical outcomes in patients with recurrent GBM treated with bevacizumab were inferior to those in previously reported studies. Clinical trials registration nr ACTRN12610000915055.
Keywords: Bevacizumab; carboplatin; glioblastoma
Rights: © The Author(s) 2015. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved.
RMID: 0030043210
DOI: 10.1093/neuonc/nov104
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.